Publications by authors named "Renan T G Oliveira"
Article Synopsis
- The pharmaceutical industry's advancements in molecular biology have transformed dermatology treatments, but rising drug costs hinder access in public health policies.
- The creation of the Specialized Pharmaceutical Assistance Component aims to make expensive drugs available, yet legal actions for medication still place a significant financial burden on state budgets.
- A study in São Paulo shows low legal demand for dermatological drugs, with psoriasis being the most common condition, suggesting the need for better access methods and cost-effective planning for new therapies.
Background: Erythrokeratodermas are a heterogeneous group of keratinization disorders. They are inherited in both autosomal dominant and autosomal recessive pattern. Erythrokeratoderma variabilis et progressive (EKVP) is a disorder caused by variations in genes that codify connexins (GJA1, GJB3, GJB4).
View Article and Find Full Text PDFPorokeratosis (PK) consists of abnormal keratinization of the epidermis of uncertain etiology and was first described by Mibelli in 1893. Multiple clinical variants of porokeratosis are recognized. The following is a case of a young male who presented more than one form of PK simultaneously.
View Article and Find Full Text PDF